Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regenxbio Inc
(NQ:
RGNX
)
11.93
-0.38 (-3.09%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regenxbio Inc
< Previous
1
2
3
4
5
Next >
Earnings Scheduled For November 3, 2022
November 03, 2022
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
Via
Benzinga
Regenxbio's Earnings Outlook
November 02, 2022
Regenxbio (NASDAQ:RGNX) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Regenxbio will...
Via
Benzinga
Despite Solid Efficacy From Gene Therapy, This Analyst Cuts REGENXBIO's Price Target
October 04, 2022
Via
Benzinga
Alphabet To $114? Plus This Analyst Predicts $145 For Disney
October 04, 2022
B of A Securities cut Alphabet Inc. (NASDAQ: GOOGL) price target from $125 to $114. Alphabet shares rose 1.9% to $100.50 in pre-market trading.
Via
Benzinga
What 4 Analyst Ratings Have To Say About Regenxbio
September 09, 2022
Within the last quarter, Regenxbio (NASDAQ:RGNX) has observed the following analyst ratings:
Via
Benzinga
4 Analysts Have This to Say About Regenxbio
August 10, 2022
Regenxbio (NASDAQ:RGNX) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
August 03, 2022
Via
Benzinga
Expert Ratings for Regenxbio
June 23, 2022
Analysts have provided the following ratings for Regenxbio (NASDAQ:RGNX) within the last quarter:
Via
Benzinga
Expert Ratings for Regenxbio
May 05, 2022
Regenxbio (NASDAQ:RGNX) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Regenxbio: Q4 Earnings Insights
March 01, 2022
Regenxbio (NASDAQ:RGNX) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Regenxbio...
Via
Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
August 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Regenxbio's Earnings Outlook
August 02, 2022
Regenxbio (NASDAQ:RGNX) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that Regenxbio will...
Via
Benzinga
5 Small-Cap S&P Stocks To Buy With The Most Upside
May 26, 2022
The S&P 500 is one of the most popular U.S. stock indices and is often what investors and experts are referring to when they mention the "stock market." However, there's more to the market than...
Via
Benzinga
Regenxbio's Return On Capital Employed Overview
May 24, 2022
Regenxbio (NASDAQ:RGNX) brought in sales totaling $22.22 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 126.09%, resulting in a loss of $76.72 million.
Via
Benzinga
Earnings Scheduled For March 1, 2022
March 01, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...
Via
Benzinga
Earnings Preview: Regenxbio
February 28, 2022
Regenxbio (NASDAQ:RGNX) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts estimate...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022
June 23, 2022
Upgrades
Via
Benzinga
Expert Ratings for Regenxbio
May 24, 2022
Over the past 3 months, 4 analysts have published their opinion on Regenxbio (NASDAQ:RGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
May 17, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
5 Value Stocks In The Healthcare Sector
May 16, 2022
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators...
Via
Benzinga
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
May 16, 2022
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from...
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
May 06, 2022
Gainers Kiromic BioPharma (NASDAQ:KRBP) stock increased by 12.6% to $0.58 during Friday's after-market session. The market value of their outstanding shares is at $8.9 million.
Via
Benzinga
83 Biggest Movers From Yesterday
May 06, 2022
Gainers Hudson Technologies, Inc. (NASDAQ: HDSN) shares jumped 26.9% to close at $9.06 on Thursday after the company reported better-than-expected Q1 EPS and sales results.
Via
Benzinga
57 Stocks Moving In Thursday's Mid-Day Session
May 05, 2022
Gainers
Via
Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
7 Top-Rated Biotech Stocks to Buy for Q2
April 21, 2022
In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill.
Via
InvestorPlace
Regenxbio's Return On Capital Employed Overview
March 07, 2022
According to Benzinga Pro, during Q4, Regenxbio (NASDAQ:RGNX) earned $294.02 million, a 603.42% increase from the preceding quarter. Regenxbio also posted a total of $398.65...
Via
Benzinga
Expert Ratings For Regenxbio
March 02, 2022
Over the past 3 months, 4 analysts have published their opinion on Regenxbio (NASDAQ:RGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
March 02, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label...
Via
Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
March 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.